BACKGROUND: In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among US children. Many sites have since reported changes in invasive pneumococcal disease (IPD). We recognized an opportunity to describe the changes in epidemiology, clinical syndromes, and serotype distribution during a 14-year period including 4 years before vaccine introduction and spanning the entire PCV7 era. METHODS: Cases were defined as children <18 years of age who were cared for at Primary Children's Medical Center for culture-confirmed IPD. We defined the prevaccine period as the time frame spanning from 1997 to 2000 and the postvaccine period from 2001 to 2010. Demographics, clinical data, and outcomes were collected through electronic query and chart review. Streptococcus pneumoniae serotyping was performed using the capsular swelling method. RESULTS: The median age of children with IPD increased from 19 months during the prevaccine period to 27 months during postvaccine period (P = 0.02), with a larger proportion of IPD among children older than 5 years. The proportion of IPD associated with pneumonia increased substantially from 29% to 50% (P < 0.001). This increase was primarily attributable to an increase in complicated pneumonia (17% to 33%, P < 0.001). Nonvaccine serotypes 7F, 19A, 22F, and 3 emerged as the dominant serotypes in the postvaccine period. In children with IPD who were younger than 5 years, for whom vaccine is recommended, 67% of the cases were caused by serotypes in 13-valent PCV during 2005 to 2010. CONCLUSIONS: After PCV7 was introduced, significant changes in IPD were noted. One-third of IPD occurred in children older than 5 years, who were outside the age-group for which PCV is recommended. Continued surveillance is warranted to identify further evolution of the epidemiology, clinical syndromes, and serotype distribution of S. pneumoniae after 13-valent PCV licensure.
BACKGROUND: In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) was licensed for use among US children. Many sites have since reported changes in invasive pneumococcal disease (IPD). We recognized an opportunity to describe the changes in epidemiology, clinical syndromes, and serotype distribution during a 14-year period including 4 years before vaccine introduction and spanning the entire PCV7 era. METHODS: Cases were defined as children <18 years of age who were cared for at Primary Children's Medical Center for culture-confirmed IPD. We defined the prevaccine period as the time frame spanning from 1997 to 2000 and the postvaccine period from 2001 to 2010. Demographics, clinical data, and outcomes were collected through electronic query and chart review. Streptococcus pneumoniae serotyping was performed using the capsular swelling method. RESULTS: The median age of children with IPD increased from 19 months during the prevaccine period to 27 months during postvaccine period (P = 0.02), with a larger proportion of IPD among children older than 5 years. The proportion of IPD associated with pneumonia increased substantially from 29% to 50% (P < 0.001). This increase was primarily attributable to an increase in complicated pneumonia (17% to 33%, P < 0.001). Nonvaccine serotypes 7F, 19A, 22F, and 3 emerged as the dominant serotypes in the postvaccine period. In children with IPD who were younger than 5 years, for whom vaccine is recommended, 67% of the cases were caused by serotypes in 13-valent PCV during 2005 to 2010. CONCLUSIONS: After PCV7 was introduced, significant changes in IPD were noted. One-third of IPD occurred in children older than 5 years, who were outside the age-group for which PCV is recommended. Continued surveillance is warranted to identify further evolution of the epidemiology, clinical syndromes, and serotype distribution of S. pneumoniae after 13-valent PCV licensure.
Authors: Krow Ampofo; Andrew T Pavia; Chris R Stockmann; Anne J Blaschke; Hsin Yi Cindy Weng; Kent E Korgenski; Judy Daly; Carrie L Byington Journal: Pediatr Infect Dis J Date: 2011-12 Impact factor: 2.129
Authors: Carrie L Byington; Matthew H Samore; Gregory J Stoddard; Steve Barlow; Judy Daly; Kent Korgenski; Sean Firth; David Glover; Jasmin Jensen; Edward O Mason; Cheryl K Shutt; Andrew T Pavia Journal: Clin Infect Dis Date: 2005-05-26 Impact factor: 9.079
Authors: Rekha Pai; Matthew R Moore; Tamara Pilishvili; Robert E Gertz; Cynthia G Whitney; Bernard Beall Journal: J Infect Dis Date: 2005-11-01 Impact factor: 5.226
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Thomas R Talbot; Katherine A Poehling; Tina V Hartert; Patrick G Arbogast; Natasha B Halasa; Ed Mitchel; William Schaffner; Allen S Craig; Kathryn M Edwards; Marie R Griffin Journal: Clin Infect Dis Date: 2004-08-16 Impact factor: 9.079
Authors: Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245
Authors: Rodrigo E Mendes; Donald Biek; Ian A Critchley; David J Farrell; Helio S Sader; Ronald N Jones Journal: Antimicrob Agents Chemother Date: 2014-05-27 Impact factor: 5.191
Authors: S Nakano; Y Matsumura; Y Ito; T Fujisawa; B Chang; S Suga; K Kato; T Yunoki; G Hotta; T Noguchi; M Yamamoto; M Nagao; S Takakura; M Ohnishi; T Ihara; S Ichiyama Journal: Eur J Clin Microbiol Infect Dis Date: 2015-08-19 Impact factor: 3.267
Authors: Liset Olarte; Krow Ampofo; Chris Stockmann; Edward O Mason; Judy A Daly; Andrew T Pavia; Carrie L Byington Journal: Pediatrics Date: 2013-06-03 Impact factor: 7.124
Authors: Chris Stockmann; Krow Ampofo; Carrie L Byington; Francis Filloux; Adam L Hersh; Anne J Blaschke; Priscilla Cowan; Kent Korgenski; Edward O Mason; Andrew T Pavia Journal: Pediatrics Date: 2013-08-26 Impact factor: 7.124